Compare Comfort Systems USA Inc (FIX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Summit Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,737.99 (market cap $60.06B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Comfort Systems USA Inc is far larger — about 4.4× Summit Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Summit Therapeutics Inc for 16 Days on average.
| FIX | SMMT | |
|---|---|---|
Market Cap | $60.06B | $13.71B |
Volume | 371,896 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $2.07K | $26.38 |
52-Week Low | $790.72 | $12.43 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | $58.53B | $13.04B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $9.1B in 2025 to $11.2B projected for 2026, supported by consistent earnings beats and a 55.29% ROE. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
Outlook remains positive with analyst consensus at Buy (55.56%) and $2,080 price target representing 19% upside. Key risks include execution of growing project backlog and sensitivity to construction cycle fluctuations. The stock's premium valuation (P/E 42.86) requires sustained high growth to justify current levels amid competitive market conditions.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
